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Anti-endothelial cell antibodies (AECAs) are thought to be
involved in the development of renal allograft rejection.
To explore this further, we determine whether AECAs play a
role both in predicting the incidence of allograft rejection
and long-term outcomes by analysis of serum samples from
226 renal allograft recipients for AECAs pre- and post-
transplant. Surprisingly, the presence of pre-existing AECAs
was not associated with either an increased risk of rejection
or a detrimental impact on recipient/graft survival.
Subsequent de novo AECAs, however, were associated with a
significantly increased risk of early acute rejection. Moreover,
these rejections tended to be more severe with a significantly
increased incidence of both steroid-resistant and multiple
episodes of acute rejection. The acute rejections associated
with de novo AECAs did not correlate with C4d deposition at
the time of renal biopsy, but did demonstrate an association
with the presence of glomerulitis and peritubular capillary
inflammation. Significantly more patients with de novo
AECAs developed graft dysfunction. Thus, our prospective
study suggests the emergence of de novo AECAs is associated
with transplant rejection that may lead to allograft
dysfunction.
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It is well recognized that antibodies against human leukocyte
antigens (HLAs), particularly those directed toward donor
antigens, can elicit an acute humoral rejection response
resulting in severe damage to the renal allograft. It has been
suggested that non-HLA antibodies might also have an
important role in the pathogenesis of allograft rejection.1,2
Vascular endothelial cells express tissue-specific antigens and,
given their critical location in any perfused organ, would
serve as first-line targets for an immune response during
allograft rejection.3,4 It has been suggested that anti-
endothelial cell antibodies (AECAs) have an important
clinical role in organ transplantation5–9 and have been
implicated as a cause of hyper-acute rejection leading to
immediate graft loss.10–15 Increasing evidence suggests a
correlation with both acute and chronic rejection.7,8,10 In the
Banff (2001) working classification of renal allograft
pathology, AECAs were proposed as one cause of antibody-
mediated rejection in addition to antibodies directed against
donor HLA.16
Despite increasing evidence suggesting their participation
in the host response to the allograft,11,17–21 the exact role of
AECAs is not known. Specifically, there have been conflicting
reports as to the value of pre-existing AECAs in the
prediction of post-transplant rejection.22 Our earlier studies
suggested that AECA-positive acute rejections are associated
with poor graft outcomes with a high risk of recurrent
episodes of rejection within the year following the inciting
event.7,8 Unfortunately, AECAs were not tested for a priori in
the earlier study and, therefore, it is not known whether
AECAs were present before transplantation or developed
de novo following exposure to foreign antigens. In this study,
serum samples were analyzed before and at different time
points post-transplantation for the presence of AECAs and
we examined the correlation between these results and
clinical outcome.
RESULTS
A total of 226 deceased-donor renal allograft recipients were
enrolled in this study. Among them, 52 recipients had pre-
existing AECAs (AECA Preþ group) before transplantation
and 22 developed de novo AECAs during the course of the
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study (AECA pre/postþ group). In 5 (9.62%) of the
52 patients with pre-existing AECAs, the antibodies were
negative post-renal transplantation. However, AECAs in the
other 47 (91.4%) patients were consistently positive (at
3 days and at 3 months post-transplantation). The significance
of pre-existing and de novo AECAs for clinical outcome was
studied separately: The 174 patients without pre-existing
AECAs (AECA Pre group) and the 152 recipients with
continuously negative AECAs (AECA pre/post group)
served as controls (Figure 1).
The significance of pre-existing AECA
Demographic data for the patients in this study are given in
Table 1. All patients received their first renal allograft. All
transplants were carried out between ABO-compatible pairs
with a negative pre-transplant complement-dependent lym-
phocytotoxicity (CDC) crossmatch (patients with positive
CDC crossmatch were not preferred to receive renal
transplantation in our Center). The panel-reactive antibody
was positive in three (5.8%) patients before transplantation
in the AECA Preþ group; their HLA-I and II antibodies were
25/17, 42/25, and 32/9.59. One patient had an acute rejection
but recovered rapidly. In the control group, the panel-reactive
antibody was positive in two patients (1.15%, P¼ 0.081) and
one of them had a recoverable acute rejection, but died from
pneumonia complications after 2 years. There was no
significant difference between the two groups with regard
to the age of recipients, the incidence of underlying
autoimmune diseases, donor age, or the cold/warm ischemia
time. There were significantly more females than males
with pre-existing circulating AECAs (34.2% (27/79) vs 17.0%
(25/147), P¼ 0.005).
Interestingly, the incidence of positive panel-reactive
antibody after transplantation and acute rejection, including
early acute rejection (within the first 2 weeks) and steroid-
resistant rejection, was similar in the two groups. Further-
more, no difference was noted in the severity of rejection
episodes as graded by the Banff (2001) working classification
of renal allograft pathology. In fact, the incidence of recurrent
acute rejections during the follow-up was higher (but not
statistically significant) in the control group (Table 2).
Protocol biopsies found no difference in the incidence of
C4d deposition. No significant correlation was found
between the presence of pre-existing AECAs with graft or
patient survival. When the patients with positive panel-
reactive antibody were excluded, there was still no significant
difference between the two groups regarding the incidence of
acute rejection and allograft survival.
Waiting list
(n = 226)
AECA(–)
(n = 174)
AECA(+)
(n = 52)
Transplantation Transplantation
AECA(pre–/post+)
(n = 22)
AECA(pre–/post–)
(n = 152)
Clinicopathological observation
Figure 1 |Group assignment.
Table 1 | Basic data of renal allograft recipients before
transplantation
AECA(+)
(n=52)
AECA()
(n=174) P-value
Age (years) 39.2±9.92 38.6±10.3 0.685
Gender (male/female) 25/27 122/52 0.005
Autoimmune diseases 1 (1.92%) 4 (2.30%) 1.000
PRA positive 3 (5.8%) 2 (1.15%) 0.081
Age of donor (years) 30.2±7.36 29.8±7.96 0.722
Previous renal transplantation 0 0 —
Cold ischemia time (h) 17.5±6.95 17.2±6.53 0.801
Warm ischemia time (min) 6.54±1.26 6.66±1.20 0.534
Baseline immunosuppressants
MMF+CsA+Pred 4 (7.7%) 38 (21.8%) 0.024
MMF+Tac+Pred 48 (92.3%) 136 (78.2%) 0.024
Aza+CsA+Pred 0 0 —
IL-2 mAb induction 49 (94.2%) 163 (93.7%) 1.000
Abbreviations: AECA, anti-endothelial cell antibody; AZA, azathioprine; CsA,
cyclosporine A; IL, interleukin; mAb, monoclonal antibody; MMF, mycophenolate
mofetil; PRA, panel-reactive antibody; Pred, prednisone; Tac, tacrolimus.
Table 2 | Complications and outcome in AECA (+) group
compared with AECA () group
AECA(+)
(n=52)
AECA()
(n=174) P-value
Acute rejection 18 (34.6%) 61 (35.1%) 1.000
Early acute rejection (o2 weeks) 11 (21.2%) 33 (19.0%) 0.695
PRA-positive post-transplantation 9 (17.3%) 27 (15.5%) 0.829
C4d deposition 8 (15.4%) 38 (21.8%) 0.432
Steroid-resistant acute rejection 5 (9.62%) 17 (9.77%) 1.000
Immunoadsorption 3 (5.77%) 10 (5.75%) 1.000
Multiple acute rejection 1 (1.92%) 14 (8.05%) 0.308
Banff grade
Normal 34 (65.4%) 113 (64.9%) 1.000
I 10 (19.2%) 38 (21.8%) 0.812
II 7 (13.5%) 21 (12.1%) 0.545
III 1 (1.92%) 2 (1.15%) 0.545
Loss of graft 6 (11.5%) 13 (7.47%) 0.394
Death 4 (7.69%) 6 (3.45%) 0.244
Abbreviations: AECA, anti-endothelial cell antibody; PRA, panel-reactive antibody.
Banff Grade I: cases with significant interstitial infiltration (425% of parenchyma
affected) and foci of tubulitis; Grade II: cases with intimal arteritis; Grade III: cases
with ‘transmural’ arteritis and/or arterial fibrinoid change and necrosis of medial
smooth muscle cells with accompanying lymphocytic inflammation.16
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The significance of de novo AECAs
Of the 174 patients without pre-existing AECAs, 22
developed de novo AECAs in the follow-up period post-
transplantation. Among them, AECAs became positive in 7
patients within 3 days post-transplantation and in 15 patients
thereafter (six patients at 3 months post-transplantation and
the other nine patients during the rejection). Compared with
the patients with continuously negative circulating AECAs,
there was no significant difference between the two groups
with regard to the recipient or donor age, recipient sex,
incidence of underlying autoimmune diseases, or cold/warm
ischemia time (Table 3). AECAs were consistently positive
throughout the study period in most (17/22, 77.3%) of the
patients. However, in five (22.7%) patients, AECAs became
negative within 6 months.
Eleven (50%) patients in the de novo AECAs group
developed acute rejection during the follow-up (nine patients
were positive during the rejection and two patients were
positive before the rejection), compared with 32.9% in the
control group (P¼ 0.151). However, although the overall
incidence of acute rejection is numerically higher in patients
with de novo AECAs, this did not reach statistical significance
(Table 4). In the patients with de novo AECAs, significantly
more patients developed steroid-resistant acute rejection
(22.7 vs 7.89%, P¼ 0.045) and multiple rejection episodes
(22.7 vs 5.92%, P¼ 0.019). Furthermore, the incidence of
early acute rejection (o2 weeks, 40.9 vs 15.8%, P¼ 0.016)
was also significantly higher in this group.
With regard to the pathological features of acute rejection
(Table 5), the incidence of C4d deposition was similar in the
two groups. The incidence of glomerulitis and peritubular
capillary inflammation was higher in the de novo AECAs
group, but the difference was not statistically significant. It
appeared that acute rejection episodes experienced by
patients in the de novo AECAs group might have a higher
incidence of vascular injury. Significantly more patients
demonstrated small vessel fibrinoid necrosis (18.2 vs 0%,
P¼ 0.030) on biopsy, as well as a slightly higher rate of
intimal arteritis (45.5 vs 36.0%). Among the patients in
Table 3 | Basic data of renal allograft recipients in AECA
(pre/post+) group compared with AECA (pre/post)
group
AECA
(pre-/post+)
(n=22)
AECA
(pre/post)
(n=152) P-value
Age (years) 38.1±8.62 38.3±10.5 1.000
Gender (male/female) 15/7 107/45 0.808
PRA positive 0 2 1.000
Age of donor (years) 29.5±4.80 29.8±8.32 0.896
Previous renal transplantation 0 0 —
Cold ischemia time 15.6±6.00 17.5±6.59 0.207
Warm ischemia time 6.95±1.50 6.62±1.15 0.216
Baseline immunosuppressants
MMF+CsA+Pred 0 38 (25%) 0.005
MMF+Tac+Pred 22 (100%) 114 (75%) 0.005
Aza+CsA+Pred 0 0 —
IL-2 mAb induction 22 (100%) 141 (92.8%) 0.363
Abbreviations: AECA, anti-endothelial cell antibody; AzA, azathioprine; CsA,
cyclosporine A; IL, interleukin; mAb, monoclonal antibody; MMF, mycophenolate
mofetil; PRA, panel-reactive antibody; Pred, prednisone; Tac, tacrolimus.
Table 4 | Complications and outcome in AECA (pre/post+)
group compared with AECA (pre/post) group
AECA
(pre/post+)
(n=22)
AECA
(pre/post)
(n=152) P-value
Acute rejection 11 (50.0%) 50 (32.9%) 0.151
Recovery of acute rejection 10/11 (90.9%) 42/50 (84.0%) 1.000
Early acute rejection (o2 weeks) 9 (40.9%) 24 (15.8%) 0.016
Positive PRA 4 (18.2%) 23 (15.1%) 0.753
C4d deposition 6 (27.3%) 32 (21.1%) 0.581
Diffuse 4 (18.2%) 19 (12.5%) 0.499
Focal 2 (9.09%) 13 (8.55%) 1.000
Steroid-resistant acute rejection 5 (22.7%) 12 (7.89%) 0.045
Multiple acute rejection 5 (22.7%) 9 (5.92%) 0.019
Graft dysfunction (serum
creatinine 41.24mg/dl)
10 (45.5%) 45 (29.6%) 0.147
Immunoadsorption 3 (13.6%) 7 (4.61%) 0.117
Loss of graft 3 (13.6%) 10 (6.58%) 0.216
Death 2 (9.09%) 4 (2.63%) 1.000
Abbreviations: AECA, anti-endothelial cell antibody; PRA, panel-reactive antibody.
Table 5 | Histological lesion of acute rejection patients in
AECA (pre/post+) group and AECA (/) group
AECA
(pre/post+)
(n=11)
AECA
(pre/post)
(n=50) P-value
Transplant glomerulopathy, n (%) 0 0
Glomerulitis with neutrophils
(n (%))
5 (45.5) 15 (30.0) 0.479
Glomerulitis with mononuclear
cells (n (%))
9 (81.8) 27 (54.0) 0.106
Tubulitis, n (%) 10 (90.9) 46 (92.0) 1.000
Tubular atrophy, n (%) 3 (27.3) 9 (18.0) 0.676
Interstitial infiltrate, n (%) 11 (100) 50 (100) 1.000
Plasma cell infiltrate, n (%) 3 (27.3) 25 (50.0) 0.201
Interstitial hemorrhage, n (%) 5 (45.5) 12 (24.0) 0.262
Interstitial fibrosis, n (%) 4 (36.4) 13 (26.0) 0.481
Mononuclear cell infiltration
in PTC, n (%)
10 (90.9) 34 (68.0) 0.159
Neutrophil infiltration in PTC,
n (%)
4 (36.4) 12 (24.0) 0.457
Intimal arteritis, n (%) 5 (45.5) 18 (36.0) 0.733
Small vessel fibrinoid necrosis 2 (18.2%) 0 0.030
Small vessel thrombi 1 (9.10%) 0 0.180
Banff 97 grade
I 6 (54.5%) 32 (64.0%) 0.733
II 3 (27.3%) 18 (36.0%) 0.733
IIA 2 (18.2%) 11 (22.0%) 1.000
IIB 1 (9.10%) 7 (14.0%) 1.000
III 2 (18.2%) 0 0.030
Abbreviations: AECA, anti-endothelial cell antibody; PTC, peritubular capillaries.
Banff Grade I: cases with significant interstitial infiltration (425% of parenchyma
affected) and foci of tubulitis; Grade IIA: cases with mild-to-moderate intimal
arteritis; IIB: cases with severe intimal arteritis comprising425% of the luminal area;
Grade III: cases with ‘transmural’ arteritis and/or arterial fibrinoid change
and necrosis of medial smooth muscle cells with accompanying lymphocytic
inflammation.39
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the de novo AECAs group, the 45.5% who experienced acute
rejection met the criteria of Banff grade II or III, compared
with 36% in the control group but the difference was not
statistically significant. There was no difference between the
two groups in this cohort with regard to plasma cell
infiltration.
With regard to overall outcome, there was no difference in
3-year survival in patients or renal allograft survival when
comparing the AECA Pre group with the AECA Preþ
group (Figure 2a and b). However, a similar analysis revealed
a significantly higher patient and allograft survival in those
persistently negative for AECAs (AECA pre/post group)
compared with the AECA pre/postþ group (90.9 vs 96.1%
(P¼ 0.034) and 94 vs 80.8% (P¼ 0.044), respectively)
(Figure 3a and b). As expected, the 3-year acute rejection-
free survival and the number of patients without graft
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Figure 2 | Impact of pre-existing anti-endothelial antibodies (AECAs) on recipient and graft survival. (a) Patient survival of AECA
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Figure 3 | Impact of de novo anti-endothelial antibodies (AECAs) on outcome of renal transplantation. (a) Patient survival of AECA
pre/postþ group compared with AECA pre/post group (P¼ 0.034 by log-rank test); (b) renal graft survival of AECA pre/postþ
group compared with AECA pre/post group (P¼ 0.044 by log-rank test); (c) acute rejection-free survival of AECA pre/postþ group
compared with AECA pre/post group (P¼ 0.044 by log-rank test); (d) graft dysfunction (serum creatinine 41.24mg/dl)-free survival of
AECA pre/postþ group compared with AECA pre/post group (P¼ 0.042 by log-rank test).
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dysfunction (serum creatinine 41.24mg/dl) was also super-
ior for the AECA pre/post group compared with the
AECA pre–/postþ group (66.1, and 70.4 vs 50.0 and 54.5%,
P¼ 0.044 and 0.042, respectively) (Figure 3c and d).
DISCUSSION
AECAs have emerged as a potentially clinically important
group of antibodies in organ transplantation. The results of
this study suggest that when compared with pre-existing
AECAs, the presence of de novo AECAs might have a much
stronger correlation with the development of post-transplant
rejection. Earlier studies provided conflicting information
with regard to the value of pre-existing AECAs in predicting
rejection,15,23–26 and no such correlation was found in this
study. The incidence of multiple acute rejections in this
cohort was even lower than that in the AECA () group.
AECAs represent a heterogeneous group of antibodies
directed against a variety of antigenic determinants expressed
on endothelial cells. Such antibodies can be detected in a
variety of autoimmune and connective tissue diseases,
especially in vascular disorder diseases.27 Unlike other
endothelial cells, human umbilical vein endothelial cells do
not express ABO blood group antigens,28 and are better
target cells for AECA detection. As AECA-positive sera
usually are negative for the presence of anti-HLA-I
antibodies, and HLA class II determinants are present
only on activated endothelial cells,29 it is currently accepted
that HLA class I and II are not targets for AECA,30 which is
why AECAs are regarded as a group of non-HLA antibodies.
If detected in pre-transplant sera, it is clearly not possible
for AECAs to be donor specific and, therefore, it would
be reasonable to assume that they would not trigger a
donor-specific alloimmune response. In our study, females
were found to have a higher incidence of pre-existing AECAs
compared with males, which is consistent with that found in
the general population, and it has been reported that the
prevalence of AECAs is usually correlated with HLA
alloimmunization,16 which could account for the observed
relationship between pre-existing AECAs and rejection. The
prevalence of allosensitization to HLA in our study was
indeed slightly higher in the pre-existing AECA (þ ) group
(5.8 vs 1.15%, P¼ 0.081) compared with the AECA ()
group, although this did not reach statistical significance.
In contrast, the emergence of de novo AECAs following
transplantation might have a stronger relationship with acute
rejection. Although the overall rates of rejection in these
patients were not significantly different when compared with
those who remained AECA (), there was a statistically
significantly higher incidence of early steroid-resistant and
multiple acute rejection episodes within this group. Given the
assay used to detect the presence of AECAs in this study, it is
not possible to say whether the newly formed AECAs are
donor specific. However, two pieces of evidence suggest that
the de novo AECAs are different from those detected pre-
transplant. First, de novo AECAs emerge following exposure
to allograft endothelial antigens; second, unlike pre-existing
AECAs, no difference in the prevalence of de novo AECAs was
detected between sexes.
Pathologically, AECAs are postulated to initiate a humoral
response leading to an increased risk of antibody-mediated
rejection. Surprisingly, we did not find a significant
association between the presence of AECAs and C4d
deposition, the classical marker of antibody-mediated rejec-
tion,31–33 regardless of whether the AECAs were pre-existing
or developed de novo. However, acute rejection episodes
related to de novo AECAs had a higher prevalence of both
glomerulitis (81.8%) and mononuclear cell infiltration in the
peritubular capillary space (90.9%), features that are
recognized as being consistent with antibody-mediated
microcirculation injury.16,34
The presence of de novo AECAs was correlated with more
severe forms of rejection, as suggested by both the increased
incidence of severe histological grading (IIB and III) by Banff
criteria and poor response to conventional steroid therapy.
Furthermore, significantly more patients developed small
vessel fibrinoid necrosis, which was consistent with this
observation. Our previous investigation, which focused on
the association of acute vascular rejection with the presence
of AECAs, demonstrated a high prevalence of plasma cell
infiltration in biopsy specimens.8,35,36 However, this finding
was not observed in the present cohort, possibly because of a
selection bias of focusing solely on vascular rejections in the
previous study.
This study confirmed our earlier observation that AECAs
are strongly associated with recurrent episodes of acute
rejection. Significantly more patients developed multiple
episode of acute rejection during the follow-up period
compared with the AECA () group (22.7 vs 5.9%,
P¼ 0.045). Also, de novo AECAs are related to steroid-
resistant acute rejection, which is consistent with the results
of our earlier study. Although rejection outcomes are better
than those for the cohort in our earlier report, significantly
more recipients with de novo AECAs developed various
degrees of renal dysfunction during the follow-up (Figure
3d). The 3-year graft survival in the patients with de novo
AECAs was significantly worse than the AECA pre/post
group (Figure 3b).
The exact role of AECAs in organ transplant immunity
remains an enigma. We have formulated two hypotheses on
the basis of the current data. First, AECAs might have a true
pathological role in inducing allograft rejection, as reported
earlier, which could explain why AECAs were detected before
the diagnosis of rejection in two cases in this study. Although
staining for C4d was negative in the majority of cases, most
patients had other signs of antibody reactivity, such as
peritubular capillary inflammation and glomerulitis. This
hypothesis suggests that patients who develop AECAs in the
post-transplant setting are at high risk for the development of
multiple episodes of acute rejection. The second hypothesis is
that AECAs are not the direct cause of acute rejection, but
rather serve as a marker of allograft injury. It is well known
that AECAs can arise secondary to pre-existing endothelial
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injury, such as ischemia/reperfusion injury and alloimmune
reactivity. Exposure of endothelial antigens following the
endothelial injury might then trigger a humoral response.
Thus, the emergence of AECA in the post-transplant
setting would serve as an epiphenomenon to a previous
injurious event.
In conclusion, our study suggests that de novo but not pre-
existing AECAs are associated with post-transplant acute
rejection. Patients with de novo AECAs are at increased risk
for multiple acute rejection, particularly in the early post-
transplant period. Definitive answers regarding this issue will
be answered only through large-scale prospective studies. An
animal model might be helpful to determine if AECAs can
lead directly to antibody-mediated rejection.
MATERIALS AND METHODS
Patients
This study included 226 cadaveric renal allograft recipients
transplanted between June 2004 and May 2008 at Jinling Hospital,
Nanjing University School of Medicine. First-time renal transplant
recipients between the ages of 18 and 65 years, who had pre-
transplant testing for the presence of AECAs, were eligible for
inclusion. Informed consent was obtained from all patients, and the
Human Subjects Committee of Jinling Hospital, Nanjing University
School of Medicine approved all study protocols. Recipients were
monitored for acute rejection episodes according to clinical criteria,
and all suspected cases were confirmed by renal biopsy.
AECAs detection
AECAs were detected by indirect immunofluorescence test using the
TITERPLANE technique developed by EUROIMMUN (Medizi-
nische Labordiagnostika AG, Lubeck, Germany) as described.8
Briefly, single cell line of cultivated human umbilical vein endothelial
cells were layered onto the reaction areas of EUROIMMUN BIOCHIP
slides and incubated with diluted serum. If a positive reaction was
obtained (indicative of specific antibodies directed against endothe-
lial antigens), the endothelial cell layer was stained with fluorescein-
labeled anti-human antibodies and visualized by fluorescence
microscopy. A positive result was manifested by the appearance of
a granular fluorescence in the cytoplasm of the human umbilical
vein endothelial cell culture. Figure 4 shows a positive versus
negative AECA staining for two patients in this cohort. The range of
normal value was a negative result at a serum titer of o1:10. We
examined serum from 90 healthy volunteers included in the study as
controls; 15 of them were positive for the presence of AECAs when
the assay was performed with undiluted serum. However, only two
were positive when the serum was diluted 1:5, and none was positive
when the serum was diluted further. AECAs were monitored pre-
transplant and at 3 days and again at 3 months post-transplant, and
whenever rejection occurred.
HLA-I, II antibodies detection and lymphocytotoxic
crossmatch
Immunoglobulin (Ig)-G anti-HLA class I and class II antibodies in
the serum samples were detected by flow cytometry as described.37
Sera with 410% reactivity for HLA class I and/or class II were
considered positive for the presence of anti-HLA antibodies. HLA-I
and II antibodies were monitored pre-transplant and at 3 days and
again at 3 months post-transplant, and whenever rejection occurred.
Pre-transplant screening for donor-specific alloantibodies was
carried out by CDC methods using the National Institutes of
Health technique with undiluted complement (without wash). A
dead cell count of o10% was considered to be representative of a
CDC-negative crossmatch. Kidney transplants were performed on
the basis of a negative pre-transplant CDC crossmatch with donor
lymphocytes. The methods described above were also used to
determine the presence of donor-specific antibodies post-transplan-
tation. Donor spleen lymphocytes were stored for future use in the
post-transplant donor-specific CDC assays.
Renal allograft pathology
Protocol biopsies were carried out at 14 days post-transplantation,
and diagnostic biopsies were performed to evaluate graft dysfunc-
tion when clinically indicated. All rejection episodes were proved by
biopsy. Two needle biopsy cores were obtained from each renal
allograft for morphological study. Each sample was divided into two
equal parts: one was fixed in formalin and the other was rapidly
frozen. Formalin-fixed tissue was routinely subjected to hematoxylin
and eosin, periodic acid Schiff, methenamine silver, and Masson
staining. Frozen tissue was examined by immunofluorescence
microscopy using a conventional panel of antibodies against IgG,
IgM, IgA, C3, C4, and C1q. C4d staining was routinely carried out
on frozen slides, using an indirect immunofluorescence technique
with a primary affinity-purified monoclonal antibody (mouse anti-
human; dilution 1:50; incubation at room temperature for 1.5 h;
Quidel, San Diego, CA) and fluorescein isothiocyanate-labeled,
affinity-purified secondary rabbit anti-mouse IgG antibody
(1:20; incubation at room temperature for 40min; DAKO,
Glostrup, Denmark). All staining was performed by standard
a b
Figure 4 |Positive and negative results of anti-endothelial cell antibodies (AECAs) detection by indirect immunofluorescence
testing. (a) Positive staining of AECA showed a granular fluorescence in the cytoplasm of the human umbilical veins endothelial cell
(HUVEC) culture, whereas nucleus was unstained. (b) Negative staining of AECA. (Original magnification,  400.)
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procedures. Positive C4d staining was defined as bright linear
staining along capillary basement membranes, involving over half of
the sampled capillaries in accord with the 2001 Banff Meeting.16,38
Initial immunosuppression
Two primary immunosuppressive protocols were used in this study:
cyclosporine A (CsA), mycophenolate mofetil (MMF), and steroids
(CsAþMMFþPred) or Tacrolimus (Tac), and MMF and steroids
(TacþMMFþPred). The main immunosuppressive protocol was
CsAþMMFþ Pred during June 2004 to June 2006 and
TacþMMFþ Pred during July 2006 to May 2008. Induction
therapy with either daclizumab or basiliximab was also used, but
thymoglobulin was not used for these patients. The initial dose of
MMF was 1.5 g/day. Calcineurin inhibitors were added when the
serum creatinine level was o50% of the pre-transplant level
(measured 1 h before the operation). Tac was initiated at a dose
0.6mg/kg per day and CsA was initiated at 4mg/kg per day. The
maintenance doses of Tac and CsA were adjusted to target specific
trough levels: 6–12 ng/ml during the first 6 months and 4–8 ng/ml
thereafter for Tac, and 150–250 ng/ml during the first 6 months and
100–200 ng/ml thereafter for CsA. Corticosteroids were administered
according to a tapering regimen consisting of an intravenous 500mg
bolus of methylprednisolone on each of days 0–2, followed by oral
prednisone 80mg/day on day 3, with a reduction of 10–20mg/day
by day 9. The dose of corticosteroid was then tapered slowly to
5mg/day.
Treatment of acute rejection
Rejection episodes were treated with bolus corticosteroid therapy
(500mg methylprednisolone, once daily for 3 days) as first-line
treatment. Concomitantly, all patients were given MMF (1.5 g/day)
and Tac (trough levels maintained at 8–15 ng/ml). For patients who
had been treated with Tac, MMF, and steroids as primary
immunosuppression, the dose of Tac was increased so that trough
levels were maintained at 8–15 ng/ml. Continuous veno-venous
hemofiltration was used for patients needing dialysis. Immuno-
adsorption was used for patients with a high level of antibodies or
very strong and diffuse C4d staining. The average follow-up time
was 36.0±16.0 (range 13–60) months.
Statistics
The results are expressed as mean±s.d. Statistical analysis was
carried out using Stata 6.0 software (Stata Corporation, College
Station, TX). Student’s t-test was used for comparing means, and w2-
test was used to test the significance of categorical variables. Survival
curves were estimated using the Kaplan–Meier method, and
differences were evaluated by the log-rank test. Po0.05 was set as
the level of statistical significance for all tests.
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